Aurora kinase A (AURKA) is located at 20q13, a region that is frequently amplified in gastric cancer. In this study, we have investigated the role of AURKA in regulating glycogen synthase kinase (GSK)-3b and b-catenin/TCF complex in gastric cancer cells. Our results demonstrate a significant increase in the phosphorylation of GSK-3b at Ser 9 following the overexpression of AURKA in AGS cells. The immunoprecipitation with antibodies specific for AURKA and GSK-3b indicated that the two proteins coexist in the same protein complex. The recombinant human AURKA protein phosphorylated the GSK-3b protein at Ser 9 in a concentrationdependent manner, in vitro. The phosphorylation of b-catenin (Ser33/37/Thr41) by GSK-3b is known to target b-catenin towards degradation. In line with our findings, the increase in phospho-GSK-3b level was accompanied by a significant decrease in b-catenin phosphorylation (Ser33/37/Thr41) and accumulation of b-catenin protein. The knockdown of AURKA reversed the phosphorylation of GSK-3b and the b-catenin protein levels. The immunofluorescence analysis demonstrated colocalization of AURKA and GSK-3b proteins and a significant increase in the nuclear b-catenin levels in cells overexpressing AURKA. The b-catenin/TCF transcription activity was measured using the pTopFlash and its mutant pFopFlash luciferase reporter vectors. Indeed, AURKA overexpression led to a significant increase in the pTopFlash reporter activity, whereas kinase dead AURKA mutant (D274A) had no effect. Consistent with these findings, we detected a significant mRNA up-regulation of several direct targets of the b-catenin/TCF transcription complex (cyclin D1, c-MYC, c-MYC-binding protein, CLDN1, FGF18 and vascular endothelial growth factor), and a two-fold increase in the proliferation rate in AURKA overexpressing cells. We conclude that the AURKA/GSK-3b interaction is important in regulating b-catenin, underscoring a novel oncogenic potential for AURKA in gastric tumorigenesis.
Introduction
Gastric cancers are characterized by poor response to therapy with unfavorable clinical outcome that reflects an inherent protective mechanism in these tumors against drug-induced apoptosis (Earle and Maroun, 1999; Jemal et al., 2006) . Aurora kinase A (AURKA) is located in chromosome arm 20q13, a locus that is frequently amplified and overexpressed in gastric adenocarcinomas (El-Rifai et al., 2001; Varis et al., 2001) . We have recently shown frequent overexpression of AURKA in adenocarcinomas of the stomach and esophagus (Dar et al., 2008) . The AURKA gene encodes a centrosome associated cell-cycle-regulated serine/ threonine kinase (Giet and Prigent, 1999) . Cytological analysis revealed that overexpression of AURKA results in centrosome amplification, cytokinesis failure; thus, production of aneuploid cells (Zhou et al., 1998) . In cancer cells, AURKA regulates several important proteins such as p53 Dar et al., 2008) , AKT (Yang et al., 2006; Dar et al., 2008) and BRCA1 (Ouchi et al., 2004) . The complete spectrum of molecular signaling mechanisms and biological functions that are regulated by AURKA are currently not fully understood.
b-Catenin is a multifunctional protein that is both an integral component of adheren junctions and a pivotal member of the Wnt signal transduction pathway. Mutations and overexpression of b-catenin disrupt the function of E-cadherins. The increased level of b-catenin through mutations in either b-catenin or adenomatous polyposis coli (APC) has been suggested to be an important oncogenic step in the genesis of a number of malignancies and it is an early event in colorectal carcinogenesis (Morin et al., 1997; Damalas et al., 1999b; Polakis, 1999) . Cytoplasmic accumulation of b-catenin results in its translocation to the nucleus where it associates with the members of TCF/LEF family of transcription factors. A large number of genes relevant for tumor formation and progression have been identified to be transcriptionally activated by the nuclear b-catenin/TCF complex (He et al., 1998; Shtutman et al., 1999; Tetsu and McCormick, 1999) . Some of them are implicated in growth control and cell cycling (cyclin D1, c-MYC, c-Jun and fra1), others are relevant for cell survival (Id2, MDR1) and some are involved in tumor invasion and metastasis (Matrilysin, vascular endothelial growth factor (VEGF); Crawford et al., 1999; Tetsu and McCormick, 1999; Koh et al., 2000; Yamada et al., 2000) . Although APC mutations are infrequent in gastric carcinomas (Nakatsuru et al., 1992) , accumulation and nuclear localization of b-catenin occurs in approximately one-third of gastric tumors (Clements et al., 2002) .
The glycogen synthase kinase (GSK)-3b is a cytosolic protein that plays a critical role in determining the levels of b-catenin in the cells. The phosphorylation of b-catenin by the kinase active GSK-3b leads to ubiquitination and proteosomal degradation of b-catenin. In this way, b-catenin is restricted from the nucleus and prevented from interacting and activating the TCF/LEF transcription complex (Aberle et al., 1997; Orford et al., 1997) . However, GSK-3b is rendered inactive after being phosphorylated at Ser 9, and thus, loses its ability to phosphorylate b-catenin leading to accumulation and nuclear localization of b-catenin (Giles et al., 2003; Kikuchi et al., 2006) . In this study, we investigated the role of AURKA in regulating GSK-3b and the effects of this regulation on b-catenin in gastric cancer cells.
Results

AURKA overexpression regulates GSK-3b phosphorylation and b-catenin protein levels
Overexpression of AURKA in AGS and SNU1 gastric cancer cells led to an up-regulation in the phosphorylation of GSK-3b (Ser 9; Figure 1a ). The GSK-3b is an important protein kinase that regulates the phosphorylation of b-catenin leading to its degradation. The phospho-GSK-3b is kinase inactive and cannot phosphorylate b-catenin, thus leading to a more stable b-catenin with its accumulation and subsequent nuclear localization that was detected as shown in Figure 4a . Consistent with our findings of increased phospho-GSK-3b in AURKA overexpressing cells, we detected a decrease in the phosphorylation level of b-catenin (Ser33/37/Thr41) together with an increase in its protein level (Figure 1b ). The use of AURKA smallinterfering RNA (siRNA) reversed these effects and led to a significant reduction in the level of phospho-GSK-3b and a subsequent decrease in the b-catenin protein level (Figure 1c ). These results suggested that AURKA can regulate the b-catenin protein levels in gastric cancer cells by regulating the phosphorylation of GSK-3b.
AURKA colocalizes and interacts with GSK-3b in AGS cells
Immunofluorescence studies using AURKA and GSK-3b-specific antibodies showed that both proteins colocalize in the cytoplasm in AGS gastric cancer cells (Figure 2a ). We and others have shown cytosolic overexpression of AURKA in several malignancies such as gastric, esophageal and lung cancer (Tong et al., 2004; Dar et al., 2008; Ogawa et al., 2008) . To confirm the protein-protein interaction, two-way co-immunoprecipitations were performed for exogenously expressed AURKA and GSK-3b ( Figure 2b ) and for endogenously expressed AURKA and GSK-3b ( Figure 2c ). The results revealed coexistence of AURKA and GSK-3b in the same protein complex. Furthermore, the in vitro kinase assay demonstrated phosphorylation of GSK-3b by AURKA in a concentration-dependent manner (Figure 2d ). The trefoil factor 1 (TFF1) protein was used as a negative control. These results confirm that AURKA can directly bind to and phosphorylate GSK-3b. The inactivation of GSK-3b by phosphorylation can be mediated by the PI3-kinase/AKT survival signaling pathway (Pap and Cooper, 1998; Mitsiades et al., 2004; Sourbier et al., 2006) . We have used AKTspecific inhibitor in the presence and absence of AURKA and demonstrated its efficacy in abrogating the phospho-AKT signals (Figure 3b ). At the same time, the AGS cells overexpressing AURKA had approximately five-fold higher signal for phospho-GSK-3b (S9) than the control cells in the presence of AKT inhibitor (Figure 3b ). These findings together with the co-immunoprecipitation results (Figures 2b and c ) and the in vitro recombinant kinase assay (Figure 2d ) support the conclusion that AURKA directly can regulate the GSK-3b phosphorylation. However, the extent of GSK-3b phosphorylation in the presence of AKT inhibitor was less than in its absence. Therefore, it is possible that AURKA regulates GSK-3b phosphorylation through direct interaction as well as through an AURKA/AKT axis-dependent mechanism.
The interaction between AURKA and GSK-3b leads to accumulation and nuclear translocation of b-catenin with activation of the b-catenin/TCF complex The aforementioned results indicated that AURKA binds to and regulates GSK-3b phosphorylation in gastric cancer cells. Consistent with our findings of increased phospho-GSK-3b in AURKA overexpressing cells, we detected a decrease in the phosphorylation level of b-catenin (Ser33/37/Thr41) together with an increase in its protein level ( Figure 1b ). Accumulation of b-catenin is a major step that promotes its nuclear localization and activates its oncogenic properties. The immunofluorescence assay on AGS cells stably overexpressing AURKA demonstrated a remarkable increase in the nuclear b-catenin, as compared to control cells ( Figure 4a ). Several reports have indicated that the oncogenic functions of b-catenin are mediated by its interaction with members of the TCF/LEF family of transcription factors in the nucleus (Behrens et al., 1996; Miller et al., 1999) . We utilized the pTopFlash/pFop-Flash luciferase vectors as a measure of b-catenin/TCF complex transcriptional activity. AURKA overexpression led to a five-fold induction of the luciferase activity of pTopFlash luciferase vector but, as expected, had no effect on the pFopFlash luciferase vector ( Figure 4b ). Conversely, expressing kinase dead AURKA mutant (D274A) did not induce luciferase activity when transfected along with pTopFlash or pFopFlash vectors; thus, indicating that the induced luciferase activity in cells transfected with pTopFlash vector is because of overexpression of kinase active AURKA. As expected, the b-catenin transfection (positive control) led to induction of pTopFlash, but not pFopFlash luciferase activity. Taken together, our results as shown in Figures  1-3 , indicate that AURKA interaction with GSK-3b regulates the b-catenin/TCF transcription activity. We have confirmed this finding by measuring the transcript Figure 2 Aurora kinase A (AURKA) colocalizes and interacts with glycogen synthase kinase (GSK)-3b. (a) Immunofluorescence assay demonstrates colocalization of AURKA (green) and GSK-3b (red) in AGS cells. (b) Co-immunoprecipitation (CO-IP) of GSK-3b and AURKA. AGS cells were cotransfected with Flag-AURKA and HA-GSK3b plasmids for 48 h. For AURKA and GSK-3b lysates were subjected to IP with Flag and HA antibodies followed by immunoblotting with HA and Flag antibodies (Cell signaling) to detect AURKA and GSK-3b, respectively. The results indicate their presence in the same protein complex. (c) The CO-IP studies were performed for endogenous AURKA and GSK-3b and demonstrated similar findings. (d) In vitro kinase assay was performed using recombinant AURKA and GSK-3b proteins followed by immunoblotting and detection with phospho-GSK-3b Ser9 antibody. GSK-3b concentration was kept constant with an increasing concentration of AURKA as indicated antibody. A concentration dependent increase in the phosphorylation GSK-3b was observed. The trefoil factor 1 (TFF1) protein was used as a negative control. level of several direct targets of the b-catenin/TCF complex. The quantitative real-time RT-PCR (qRT-PCR) indicated up-regulation of cyclin D1, c-MYC, c-MYC-binding protein, CLDN1, FGF-18 and VEGF in AURKA overexpressing cells as compared to control ( Figure 5a ). Using cyclin D1 as an example of these targets, we further confirmed the induction of its promoter in AURKA overexpressing cells (Figure 5b ) and demonstrated the increase in its protein level in AGS and SNU1 cells ( Figure 5c ). Cyclin D1 is important in cell cycle and proliferation. Indeed, AGS cells stably expressing AURKA showed >2.5-fold increase in their proliferation rate as compared to control vector cells, as determined by 5-Bromo-2 0 -deoxyuridine (BrdU) incorporation assay (Figure 6a ). The cell-cycle analysis demonstrated a doubling in the Sphase in AGS (from 10 to 18%) and RIE (from 6.5 to 16%) cells overexpressing AURKA as compared to control vector-expressing cells (Figures 6b and c) . Taken together, these results indicate that the AURKA/GSK-3b interaction results in a functional signaling outcome that is manifested by an increase in the b-catenin protein, activation of the b-catenin/TCF transcription complex and increase in the cell proliferation rate. Other oncogenic consequences of the AURKA/GSK-3b interaction and nuclear accumulation and activation of b-catenin remain to be elucidated in further studies.
Discussion
Gastric cancers are characterized by poor response to therapy with unfavorable clinical outcome that reflects an inherent protective mechanism in these tumors against drug-induced apoptosis (Earle and Maroun, 1999; Jemal et al., 2006) . The critical molecular alterations and signaling pathways that drive gastric tumorigenesis remain largely uncharacterized. In this study, we have investigated the role of AURKA in this devastating disease. AURKA is located at chromosome 20q and is frequently amplified and overexpressed in gastric cancer (El-Rifai et al., 2001; Varis et al., 2001; Kamada et al., 2004; Dar et al., 2008) . We and others have shown AURKA overexpression in a wide range of primary tumors including adenocarcinomas of the breast, colorectal, pancreatic, ovarian, esophageal, gastric and bladder cancers (Bischoff et al., 1998; Zhou et al., 1998; Tanaka et al., 1999; Kamada et al., 2004; Giet et al., 2005; Hu et al., 2005) .
In this study, we have demonstrated that AURKA interacts with GSK-3b and directly binds to and phosphorylates GSK-3b at Ser 9. The GSK-3b has been previously identified as a key downstream target of the PI3-kinase/AKT survival signaling pathway (Pap and Cooper, 1998; Mitsiades et al., 2004; Sourbier et al., 2006) . We have used AKT-specific inhibitor in the presence and absence of AURKA and our results demonstrated a high level of phospho-GSK-3b (S9) in the presence of AKT inhibitor in AURKA overexpressing cells, supporting our notion that AURKA can directly regulate GSK-3b. It is worth mentioning that we and others have shown that AURKA can phosphorylate and activate AKT (Yang et al., 2006; Dar et al., 2008) . Therefore, it is possible that AURKA regulates GSK-3b phosphorylation through direct interaction and/or through AURKA/AKT axisdependent mechanism. GSK-3b is a major protein kinase that regulates the phosphorylation of b-catenin in the cytoplasm, targeting it to degradation (Kikuchi et al., 2006; Giles et al., 2007) . The inactivation of GSK-3b by phosphorylation has been shown to reduce the ubiquitination of b-catenin, resulting in nuclear accumulation and transcriptional activity of b-catenin (Giles et al., 2003; Kikuchi et al., 2006) . Indeed, we detected a decrease in the phosphorylation level of b-catenin (Ser33/37/Thr41) together with a significant up-regulation in the total b-catenin protein levels following overexpression of AURKA in AGS and SNU1 cells. These results suggested that down-regulation in the phosphorylation of b-catenin (Ser 33/37/Thr41) has ultimately led to an accumulation of b-catenin in AURKA overexpressing cells. We have validated our results using siRNA knockdown of AURKA and demonstrated a significant decrease of phosphorylated GSK-3b (Ser 9) and b-catenin protein levels.
Up-regulation of b-catenin and its nuclear accumulation has been reported to play a major role in gastric cancer (Morin et al., 1997; Washington et al., 1998; Clements et al., 2002) . Accumulation of the b-catenin protein is attributed to either mutation of APC or b-catenin itself. One of the most widely observed mechanisms for regulating b-catenin in cancer cells involves mutations in APC gene that is an important oncogenic step in the genesis of a number of malignancies and it is an early event in colorectal carcinogenesis (Morin et al., 1997; Damalas et al., 1999a; Polakis, 1999) . Mutations in b-catenin have been identified in many human tumors, including hepatocellular carcinoma (Terris et al., 1999) , colorectal cancer , ovarian cancer (Gamallo et al., 1999) and The luciferase reporter assay using pTopFlash and its mutant pFopFlash vectors was utilized to study the b-catenin TCF/LEF transcriptional activity. The pTopFlash reporter vector has six TCF-binding sites, although pFopFlash has mutated TCFbinding sites. AGS cells were cotransfected with different expression vectors as indicated. Overexpressing AURKA along with pTopFlash vector resulted in the induction of luciferase activity, indicating the transcription activity of the b-catenin/TCF complex. The kinase dead AURKA mutant (D274A) had no effect on pTopFlash activity. The wild-type b-catenin-expressing vector (pSWTBCAT) was used as a positive control. The overexpression of AURKA or its kinase dead mutant (D274A) with pFopFlash vectors had no effect on the luciferase activity. Luciferase activity was measured using a Dual luciferase reporter assay kit (Promega) following manufacturer's instructions. Results were averaged from three independent experiments and expressed as mean values ( ± standard deviation (s.d.)). prostate cancer (Voeller et al., 1998) . Although APC mutations are rare in gastric carcinomas (Nakatsuru et al., 1992) , accumulation and nuclear localization of b-catenin occur in approximately one-third of gastric tumors (Clements et al., 2002) . Therefore, the AURKA/ GSK-3b axis may explain some of these findings.
Several reports have indicated that the oncogenic functions of b-catenin are mediated by the nuclear fraction because of its interaction with the members of the TCF/LEF family of transcription factors. The b-catenin/TCF transcription complex regulates the expression of several genes that are involved in human carcinogenesis such as cyclin D1 and c-MYC (He et al., 1998; Pennica et al., 1998; Crawford et al., 1999; Shtutman et al., 1999; Hojilla et al., 2007) . Indeed, our results demonstrate up-regulation and nuclear localization of b-catenin. The AURKA overexpression increased the pTopFlash luciferase activity whereas the kinase dead AURKA mutant (D274A) did not induce this activity, confirming the role of the kinase active AURKA. Furthermore, we demonstrated the mRNA up-regulation of several direct transcription targets of the b-catenin/TCF complex; cyclin D1, cMYC, cMYC-binding protein, CLDN1, FGF18 and VEGF (A list of targets of b-catenin/TCF is available at http://www. stanford.edu/Brnusse/pathways/targets.html, with specific references for each of them). Taken together, these results indicate that overexpression of AURKA leads to an increase in b-catenin protein level with induction of its nuclear translocation and activation of the b-catenin/TCF transcriptional activity.
Cyclin D1 is a transcription target of the b-catenin/ TCF complex that is important in cell proliferation, tumor progression and metastasis (Zhang et al., 1993; Wang et al., 2004) . We have demonstrated induction of its promoter activity following AURKA overexpression. The AGS cells stably expressing AURKA showed more than two-fold increase in their proliferation rate as compared to control vector cells and demonstrated an almost doubling in the S-phase of cells overexpressing AURKA as compared to control vector-expressing cells. The increase in b-catenin level promotes neoplastic conversion and plays distinct roles in uncontrolled progression into the cell cycle through the G 1 phase (Sherr and Roberts, 1999; Shtutman et al., 1999; Tetsu and McCormick, 1999) . Our results suggest that AURKA/GSK-3b axis, by regulating b-catenin, may play a critical role in this process in gastric cancer cells.
In summary, our results demonstrate that AURKA regulates the GSK-3b phosphorylation and activity leading to accumulation and activation of the b-catenin/TCF complex in gastric cancers. The AURKA/GSK-3b axis underscores a novel angle for the role of AURKA in cancer where other biological and cell signaling consequences of this axis remain to be elucidated in further studies.
Materials and methods
Cell culture, vectors, small-interfering RNA and transfection AGS, SNU1, SNU16, MKN45, MKN75, and RIE-1 cells were cultured in F-12 (HAM) or Dulbecco's modified Eagle's medium together with 10% fetal bovine serum (Invitrogen Life Technologies, Carlsbad, CA, USA) at 37 1C in an atmosphere containing 5% CO 2 . AGS, SNU1 and SNU16 cells were obtained from American Tissue Culture Collection (ATCC, Manassas, VA, USA). MKN45 cells were obtained from the German Collection of Microorganisms and Cell Cultures (Braunschweig Germany). The MKN75 cells were a gift from Dr Barbara Schneider and the RIE-1 cells were obtained from Dr Robert J Coffey, Jr (Vanderbilt University, Nashville, TN, USA). The expression plasmid for AURKA was generated by PCR amplification of the full-length-coding sequence of AURKA and cloned in frame into pcDNA3.1 (Invitrogen Life Technologies). A synthetic Flag-tag sequence was added at the N terminus of AURKA. Cloning of AURKA was confirmed by sequencing and restriction enzyme digestion. pSWTBCAT plasmid (wild-type b-catenin cloned into p-shuttle backbone vector from Clontech, Mount View, CA, USA) was a kind gift from Dr Andy Lowy (University of California, San Diego). Retroviral expression constructs, pBabe-puro, containing either the full length of AURKAcoding sequence (pBabe-AURKA) or a kinase-dead AURKA mutant (D274A) and HA-GSK-3b pcDNA were purchased from Addgene (Cambridge, MA, USA). Validated siRNA oligonucleotides specific for AURKA and negative control siRNA were purchased from Ambion (Austin, TX, USA). Transient transfections were performed by using Fugene-6 (Roche Applied Science, Indianapolis, IN, USA), and Lipofectamine (Invitrogen Life Technologies, Carlsbad, CA, USA) following the manufacturer's protocols. Recombinant active GSK-3b and AURKA proteins were purchased from Figure 6 Aurora kinase A (AURKA) overexpression enhances cell proliferation of gastric cancer cells. (a) AGS cells stably expressing AURKA showed enhancement in the cell proliferation as evidenced by the 5-Bromo-2 0 -deoxyuridine (BrdU) incorporation assay. BrdU assay was performed by using the BrdU labeling and detection kit I (Roche Applied Science), following the manufacturer's protocol. Quantification of BrdU-positive-stained cells indicated X2.5-fold increase in the cell proliferation of AGS cells expressing AURKA compared to control vector-expressing cells (bar graph). The results represent the average of three independent stable clones. Western blot demonstrates the overexpression of AGS cells stably overexpressing AURKA. (b) Cell cycle analysis of AGS cells overexpressing AURKA indicated an almost doubling of the S-phase (10-18%) as compared to control vector-expressing cells. Transfection of AGS cells with b-catenin-expressing vector (pSWTBCAT) was used as a positive control. (c) Primary gastrointestinal epithelial RIE-1 cells transduced with AURKA retroviruses showed more proliferation than cells transduced with control retroviruses as determined by an increase from 6.5 to 16% in the S-phase of cell cycle.
BioVision (Mountain View, CA, USA) and Cell Sciences (Canton, MA, USA), respectively. AKT inhibitor VIII was purchased from Calbiochem (Gibbstown, NJ, USA) and AGS cells overexpressing AURKA or control vector were treated with 1 mM of AKT inhibitor VIII for 24 h.
Luciferase assays
The TCF-responsive luciferase construct pTopFlash, its mutant pFopFlash (Upstate Biotechnology, Waltham, MA, USA) and cyclin D1-Luc (Tetsu and McCormick, 1999) were used to study the transcriptional activity. The pTopFlash vector has six TCF-binding sites, each three in the opposite direction. The pFopFlash, a negative control, has mutant TCF-binding sites. The luciferase activity was determined using a dual-luciferase reporter assay kit (Promega, Madison, WI, USA). The relative luciferase activity was determined after 48 h of transfection and normalized to protein concentration. Results are average of three independent experiments and expressed as mean values ( ± standard deviation (s.d.) ).
Fluorescence-activated cell sorting
Cell-cycle analysis was performed using flow cytometry. Cells were synchronized by culture in the presence of 1% fetal bovine serum for 24 h, followed by 10% fetal bovine serum. Cells were trypsinized, washed twice with 1 Â ice-cold phosphate buffer saline (PBS) and then resuspended in 0.2 ml ice-cold PBS. Cells were then fixed in 1 ml ice-cold 70% ethanol and incubated for 1 h at 4 1C. Cells were centrifuged and resuspended in 1 ml PBS and treated with propidium iodide (50 mg/ml) and RNase (1 mg/ml) for 30 min at 371C and analysed by BD LSR III flow cytometer (BD Biosciences, San Jose, CA, USA). Data were analysed by BD FACS Diva software.
Western blot analysis
Cell lysates were prepared in 1 Â PBS buffer containing 1 Â Halt protease inhibitor cocktail and 1 Â Halt phosphatase inhibitor cocktail (Pierce, Rockford, IL, USA), centrifuged at 3500 r.p.m. for 10 min at 41C. Protein concentration was measured using a Bio-Rad protein assay (Bio-Rad Laboratories, Hercules, CA, USA). Proteins (10-15 mg) from each sample were subjected to SDS/polyacrylamide gel electrophoresis (PAGE) and transferred onto nitrocellulose membrane. Target proteins were detected by using specific antibodies against AURKA (TransGenic Inc., Japan); b-actin, b-catenin, phospho-b-catenin (Ser33/37/Thr41), GSK-3b, phospho-GSK3b (Ser 9), cyclin D1, AKT, pAKT(S473), HA-tag and Flag (Cell Signaling Technology, Boston, MA, USA). 5-Bromo-2 0 -deoxyuridine labeling and detection 5-Bromo-2 0 -deoxyuridine labeling was performed using the BrdU labeling and detection kit I (Roche Applied Science), following the manufacturer's protocol. In brief, cells were grown in an eight-well chamber and BrdU-labeling medium was added to cells and incubated at 371C for 3 h. Cells were washed once with 1 Â PBS followed by ethanol fixation for 20 min at À201C. After washing cells, anti-BrdU reagent was added for 30 min at 371C. For fluorescence detection, antimouse immunoglobulin fluorescein was added and incubated for 30 min. Cells were visualized under an Olympus BX51 fluorescence microscope (Olympus Co., Tokyo, Japan).
Immunoprecipitation
Cells (5 Â 10 6 ) were centrifuged for 5 min at 1500 r.p.m. After discarding the supernatant, cell pellet was resuspended in RIPA buffer. Samples were sonicated 3 Â for 10 s and centrifuged for 20 min at maximum speed (13 000 r.p.m., 41C). Supernatants were collected into new tubes and 50 ml of protein G-Agarose were added to samples and incubated at 41C for 10 min. Samples were then centrifuged for 15 min and divided into three tubes. Specific and nonspecific antibodies were added to their respective tubes containing protein samples and incubated on ice for 15 min. Briefly, 50 ml of protein G-Agarose beads were added to each tube and incubated on a rotating platform at 41C overnight. Samples were centrifuged for 1 min and washed 8 Â with RIPA buffer. Briefly, 20 ml of 2 Â protein-loading buffer were added to each sample and boiled for 5 min. Samples were resolved by SDS/ PAGE and subjected to western blotting.
Quantitative real-time RT-PCR Total RNA was isolated using the RNeasy mini kit (Qiagen, Valencia, CA, USA), and single-stranded cDNA was subsequently synthesized using the Advantage RT-for-PCR Kit (Clontech, Palo Alto, CA, USA). Gene-specific primers for cyclin D1, c-MYC, c-MYC-binding protein, CLDN1, FGF18, VEGF and HPRT1 were designed using the online software, Primer 3 (http://frodo.wi.mit.edu/cgi-bin/ primer3/primer3_www.cgi). The forward and the reverse primers were designed to span two different exons. All primers were purchased from GeneLink (Hawthorne, NY, USA) and their sequences are available from the authors upon request. qRT-PCR was performed using an iCycler (Bio-Rad Laboratories) with a threshold cycle number determined with the use of iCycler software version 3.0. Reactions were performed in triplicate and threshold cycle numbers were averaged. The results were normalized to HPRT1 as described earlier (El-Rifai et al., 2002) . The fold change in all samples was calculated according to the formula 2 (RtÀEt) /2 (RnÀEn) , as described previously (El-Rifai et al., 2002) .
In vitro kinase assay
The in vitro kinase assay was performed using active recombinant AURKA (Cell sciences, Canton, MA, USA) and recombinant GSK-3b (BioVision, Mountain View, CA, USA) following the manufacturer's protocol. Briefly, reaction was carried out in 20 ml of assay buffer (50 mM HEPES, pH7.4 þ 3 mM Mgcl 2 þ 3 mM Mncl 2 þ 1 mM DTT þ 3 mM Naorthovanadate þ 0.5 mM ATP) containing a constant concentration of 0.2 mg of GSK-3b and increasing concentrations from 0.1 to 0.8 mg of human recombinant AURKA. The TFF1 protein (Abnova, Taipei City, Taiwan) was used as a negative control as it is not a phospho protein and is not known to interact with AURKA or GSK-3b. Reaction mixtures were incubated at 301C for 30 min. Briefly, 6 ml of 2 Â proteinloading buffer was added to each sample and boiled for 5 min. Samples were resolved by SDS/PAGE and subjected to western blotting using specific antibodies for AURKA and pGSK-3b Ser 9.
Immunofluorescence assay AGS cells (3 Â 10 3 per well) were plated in eight-well plate chamber for 24 h. Cells were washed with 1 Â PBS and fixed with acetone/methanol (1:1) mixture for 15 min at À201C. Cells were then washed twice with 1 Â PBS, followed by blocking with 10% normal goat serum blocking solution (Zymed Laboratories, Carlsbad, CA, USA) for 20 min at room temperature in a humidified chamber. Cells were hybridized with the specific primary antibodies against AURKA, b-catenin or GSK-3b (Cell Signaling, Danvers, MA, USA) diluted in 1 Â PBS (1:400) for 2 h at room temperature in a humidified chamber. Cells were washed three times in 1 Â PBS and hybridized with fluorescently conjugated secondary antibody (1:1000; Jackson Immunoresearch, West Grove, PA, USA) for 45 min at room temperature in a humidified chamber. AURKA and b-catenin were detected by fluorescein isothiocyanate green fluorescence and GSK-3b by tetramethylrhodamine isothiocyanate (red fluorescence). Cells were washed in 1 Â PBS, mounted with Vectashield/DAPI (Vector Laboratories, Burlingame, CA, USA) and visualized by an Olympus BX51 fluorescence microscope (Olympus Co., Tokyo, Japan). At least 200 cells were counted from each experiment.
